Watch Our TV Infomercial
Real customers tell all!
  1. Zulma
    Type 2 Who Lost Sugar Cravings & Lost 7 lbs. Has LOTS More Energy!
  2. Kelly
    User has "Through the Roof Energy," Better Sleep and Toxins Out.
  3. Daryl
    Daryl MicrobeFiber™ Customer, Way Better Digestion and Energy!
  4. Connie
    Customer Lost 40 LBS! Her Story...
  5. Alex White, MD
    Explains what to Expect After 30 Days on MicrobeFiber™
  6. Alex White, MD
    Explains what to Expect After 60 Days on MicrobeFiber™

100% Natural, No Additives & Chemical Free!

Trial Participants Report Improvements With...
Sleep, Inflammation, Allergies, Digestion, Candida, Stools & Energy*

  1. Maria Constalani
    "Taking pain medication... I was very irregular. Once I started taking the MicrobeFiber™, I'm just real regular... like a normal person!"
  2. Emily Morris
    "As soon as I started taking it, I started to feel the effects of it. It was immediate.... I was like an Energizer Bunny!"
  3. Tony Welch
    Challenges: Diabetes/Obesity "MicrobeFiber™ Saved my life." *
  4. Dorothy
    "Heartburn, leg cramps, even a hospital visit. I have to attribute all of my wellness now to the MicrobeFiber™."
  5. Elizabeth
    "I'm sleeping better, I feel rested, I don't feel so anxious."
  6. Nora's amazing weight loss story.
  7. Daryl & Family Lost Weight with MicrobeFiber™

Mix 1 scoop into your coffee, water, shakes or ANY food you prepare.
You won't even know it's in there (mixed in water it has an ever so subtle sweet taste).

  1. Jess
    "I had issues in my stomach and severe pains in my lower intestines. Within 30-45 days, I had great results quite frankly and I've been using it ever since."*
  2. Robert Harris
    "Once you get your gut healthy, you can flourish. I would recommend it to anyone."
  3. Robert Harris updated
    Updated Testimony "I stopped taking it for 2 months to see if it was really the MicrobeFiber that was helping me."
  4. Angelita
    "Helped my motivation and energy."
  5. Nancy
    "My sleep patterns improved and my mood improved"
  6. Amancio
    Since 1991, I've had diabetes. neuropathy, eye problems... I was a wreck. 30 days on MicrobeFiber™, my blood sugar numbers are down 100 points..I'm not in as much pain anymore..something positive is happening"*
Clinical Trials
While research is only just beginning, the first 2 clinical trials we conducted to evaluate the effects of MicrobeFiber on Prediabetes and Type II Diabetes and also healthy obese males and females demonstrated an average A1C decrease of 0.97 and an average weight loss of 5.8 lbs. (See Clinical Trials Below)*
A 52 week pilot study to evaluate the effects of MICROBFIBER on body weight on healthy obese male and female patients.
A 26 week study to evaluate the safety and efficiency of MICROBEFIBER on Prediabetes and Type II Diabetes Mellitus on patients either naïve to treatment or on stable regimen for the past 12 weeks.
Type II diabetes mellitus is a growing health concern in the US and throughout the world. Projections show a continued increase in the incidence of this disease and the associated significant complications. There is recognition that prevention and effective disease modifying therapies are needed in spite of the current available medications. The goal of diabetes treatment is to have an effective lowering of Hemoglobin A1c while not causing weight gain or inducing hypoglycemia.
Summary of Study Design

MFPD-T2DM-003 protocol was a pilot study to evaluate the efficacy of MICROBEFIBER administered 3 times daily over 24 weeks in patients with prediabetes and Type 2 diabetes mellitus (T2DM) drug naïve or as add-on therapies in patients on a stable drug regimen. 

Multiple parameters were evaluated including change in Hemoglobin A1c, effect on body weight, waist circumference and other exploratory endpoints. The intent was to determine the ideal subject population for future clinical trials.

We felt it was important to hold MicrobeFiber™ to the rigors of other clinical trials to allow for a comparison to the pharmaceutical agents currently available for the treatment of Type 2 DM. The duration needed to be sufficient to see a difference in the treatment group as compared to the control group. Both the treatment and control group were randomly selected and each was given intensive dietary education and regular monitoring and accountability. 

There were 2 categories of patients:

Pre-diabetes or controlled diabetics with A1c <7.0
Diabetics with a baseline A1c > 7.0 ranging as high as 11.2
The demographics are summarized as males 65%, females 35% average age 58 years old with average A1c 8.3 with 13 years average duration of diabetes. 
Summary of Results

There were a total of 42 patients randomized to either control group or active MicrobeFiber™ treatment group. Both groups received structured dietary instruction based on ADA guidelines and regular re-enforcement and accountability. Subjects kept diaries to determine compliance with carbohydrate intake.

There were 23 subjects with a baseline A1c > 7 randomized to MicrobeFiber™ and 5 subjects with A1c > 7 randomized to the control group. Clinical trials in type 2 DM evaluate therapies by measuring the proportion of patients achieving a clinically relevant composite result of a Hemoglobin A1c < 7 without causing weigh gain or hypoglycemia.

Of the 23 MicrobeFiber™ subjects, 6 achieved an A1c < 7 or 26%. In contrast none of the control group reached A1c < 7. The majority of the subjects in the MicrobeFiber™ (15/23 or 65.2%) had a reduction A1c with an average decrease of 0.97 which is comparable or better than what is expected to be achieved by use of pharmaceuticals (see table 1). The average decline in A1c all subjects in the MICROBEFIBER treatment group was 0.43 as compared to an actual increase of 0.28 in the control group.

In addition to a robust reduction in A1c in the MICROBEFIBER treatment group, there was also noted to be significant weight loss (16/23 or 70%). This was an average weight loss of 5.8lbs. A measurement of the waist circumference also was notable with 19/23 having a decrease or no change. This amounts to an average loss of 0.86 inches. The composite of either weight loss or waist circumference reduction was 19/23 or 82.6%. In the control group there was no discernable change in either weight or waist circumference.

There was no clear signal for change in A1c in the group of subjects with A1c < 7.0 treated with MicrobeFiber™. However, 10/12 or 83.3% lost weight with the average weight loss of 6.4lbs. Waist circumference also improved significantly in 10/12 or 83.3% of this group with an average decrease of 1.6 inches. 

Subjects with a baseline A1c > 7.0 treated with MICROBEFIBER achieved comparable or superior results when pharmaceuticals currently being used in the treatment of Type II DM. There was good weight reduction and none of the MicrobeFiber™ patients had any incidence of hypoglycemia. When taking into account the composite of the proportion achieved goal of A1c < 7, no weight gain and no hypoglycemia, MICROBEFIBER has a very favorable profile as summarized in the table 1. 

There are no clear strategies on how to utilize known medications in pre-diabetics (A1c < 7). The approached used in the medical community focuses on lifestyle modification. It was clear that the MicrobeFiber™ treated group had a notable improvement in body weight and weight circumference. Ongoing research recognizes that modification of weight and decreasing central obesity has a beneficial effect on cytokines and other markers possibly correlating to improvement in health outcomes.

Further evaluation into other exploratory end points will be undertaken. A larger scale IRB approved and monitored clinical trial is crucial for MicrobeFiber™ in order to obtain data that will be statically significant allowing for publication and promotion. 

There were 2 protocols, one for women and one for men, designed as a pilot program to determine the effects of MICROBFIBER on body weight and waist circumference. It was also intended to monitor for side effects of the study treatment as well as other exploratory end points. 

Summary of Study Design

This was a single-site trial involving healthy obese male and female subjects 18 years of age and older with a BMI of > 30. Subjects came in every 2 weeks for 52 weeks to determine compliance and capture adverse events. The subjects were taking 10g of MICROBFIBER three times a day (TID) with each meal. Subjects had blood pressure measured, BMI calculated, waist measured, physical exam, and safety labs during office visits. 

Summary For Female Results

There were a total of 20 subjects who participated and deemed compliant with study requirements*. Of the 20 subjects, 50% (which will be referred to as “Responders”) had a weight reduction. Among the Responders, there was an average weight loss of 32.2 lbs. which translated into an 11.5% decrease in body weight (average weight was 279.2lbs). Even taking into account both Responders and Non-Responders, there was an average weight loss of 8.8 lbs or 3.4% reduction of body weight (average weight 259.5 lbs).
Waistline Measurements
Among all 20 female subjects, 70% showed a reduction in waist circumference. The average decrease of all subjects was 3.4 inches and in the Responder group (weight loss), there was a decrease of 6.5 inches. 
Summary For Male Results

There were a total of 27 subjects participating*. The Responders among the men totaled 52% (14/27) that accounted for an average weight loss of 14.5 pounds or 6.1% decrease in weight (average weight 253.7). Looking at Responders and Non-Responders, there was an average weight loss of 3.2 lbs per subject, or a 3.1% decrease. 
Waistline Measurements
Again here we see 52% or 14/27 lost inches around the waist. The Responders lost an average of 3.7 inches per subject and among all 27 subjects there was a 2.4 inch decrease. 

Cumulative Results
Of all the subjects, 83% (39/47) either lost weight, inches, or both. Almost all subjects reported increase in energy and improved mood. About half reported that they had better quality of sleep, saying that they felt they were getting a more restful night sleep. 

Adverse Events

Most of the male and female subjects reported having intestinal gas (flatulence), feeling bloated and minor abdominal cramps the first 2-3 weeks (visit 3) of taking the study treatment. This mostly went away by the 4th week (visit 4). However, there was only one subject who continued to have gastrointestinal symptomatology throughout the study but this was not concerning to her.

*If subject did not complete the 52 weeks the final visit was used in calculations. 

"And he said unto them, ye will surely say unto me this proverb, Physician, heal thyself "
Dr. White
Is a Board-Certified Clinical Trial Physician with 15 years in in study related sciences and 25 years as an ER doctor and hospitalist. Dr. White is driven by science and desires for all to include MicrobeFiber™ into their daily diets. Dr. White is very hands on and encourages anyone to write him with any questions of a medical nature related to taking MicrobeFiber™.